Bosh sahifaFTRE • NASDAQ
add
Fortrea Holdings Inc
Yopilish kursi
20,69 $
Kunlik diapazon
20,87 $ - 21,60 $
Yillik diapazon
16,53 $ - 41,02 $
Bozor kapitalizatsiyasi
1,84 mlrd USD
Oʻrtacha hajm
1,33 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 674,90 mln | -5,45% |
Joriy xarajat | 157,50 mln | 21,53% |
Sof foyda | -27,90 mln | -99,29% |
Sof foyda marjasi | -4,13 | -110,71% |
Har bir ulushga tushum | 0,23 | -4,17% |
EBITDA | 12,00 mln | -72,22% |
Amaldagi soliq stavkasi | 48,32% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 105,30 mln | -4,01% |
Jami aktivlari | 3,66 mlrd | -15,13% |
Jami passivlari | 2,15 mlrd | -18,01% |
Umumiy kapital | 1,51 mlrd | — |
Tarqatilgan aksiyalar | 89,70 mln | — |
Narxi/balansdagi bahosi | 1,23 | — |
Aktivlardan daromad | -0,64% | — |
Kapitaldan daromad | -0,85% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | -27,90 mln | -99,29% |
Operatsiyalardan naqd pul | -2,40 mln | -226,32% |
Sarmoyadan naqd pul | -8,10 mln | -400,00% |
Moliyadan naqd pul | -14,00 mln | -81,82% |
Naqd pulning sof oʻzgarishi | -20,90 mln | -309,80% |
Boʻsh pul | -19,35 mln | -269,37% |
Haqida
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Tashkil etilgan
apr 1996
Sayt
Xodimlar soni
15 500